Transglutaminase 2

Monoclonal antibody to human TG2 (Catalytic Domain, clone XTG17)

(antibody reacts with the Core Domain of transglutaminase 2
[human, guinea pig, rat, mouse and dog TG2])

200 µg 400 € available

Art. No. A033
Background info Tissue transglutaminase is a, Ca2+-dependent enzyme (78 kDa) composed by 4 domains:
Beta Sheet Domain (fibronectin binding, ~17 kDa), catalytic Core Domain (Cys-His-Asp catalytic triad, Calcium-binding, GTP/GDP-binding, ~37 kDa), Beta Barrel 1 Domain (GTP/GDP-binding, ~14 kDa) and Beta Barrel 2 Domain (~12 kDa). The inactive GTP-bound enzyme is present in a closed conformation, which upon activation by Ca2+ and substrate binding opens like a pocket knife resulting in a longitudinal open conformation.
Host Mouse
Immunogen Human tissue transglutaminase (full length protein with N-terminal hexahistidin-tag) recombinantly produced in insect cells
Specificity Mouse monoclonal antibody reacts with the catalytic Core Domain of TG2
(human, guinea pig, rat, mouse and dog TG2)
Specificity of A033 was determined in western blotting with human transglutaminases (TG1 – TG7, FXIII), TG2 of different species and human TG2 domains recombinantly produced in E. coli.
A033 is specific for the catalytic Core Domain of TG2. It does not cross-react with other
domains of human TG2.
A033 is specific for TG2. It does not cross-react with other human transglutaminases.
A033 recognizes human, guinea pig, rat, mouse and to a weak extend dog TG2.

A033 recognizes the epitope D438ITHTYKYPE447 (see figure in PDS). The epitope was determined using PEPperCHIP® Transglutaminase Microarray (Art. No. P111).

For more information klick here:
Poster presentation at GRC, 2016 (Girona, Spain)
Appearance liquid
Description Protein G-affinity purified mouse monoclonal antibody.
Reagents 75 mM NaCl, 5 mM Tris, pH7.5, 0.025% sodium azide, 50% glycerol.
Application Western-Blotting, Immunofluorescence
Working dilutions Optimal dilutions should be determined by the end user.
E. g. for Western-Blotting: 1 / 500 to 1 / 5,000 should be suitable
Storage Store at -80°C.
If storage at -80°C is not possible, storage at ≤ -20°C is recommended. Stable for short term at +4°C.
Delivery is possible at ambient temperature.
Reference(s) Kanchan et al., Cell. Mol. Life Sci. 2015, 72:3009-35
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • Canceled: Gordon Research Conference - Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy